Hsp90 Inhibitors for Parkinson's Disease
Overview <table class="infobox infobox-therapeutic">
...
Hsp90 Inhibitors for Parkinson's Disease
Overview <table class="infobox infobox-therapeutic">
Hsp90 (Heat Shock Protein 90) is a highly abundant molecular chaperone that plays a critical role in protein folding, quality control, and cellular homeostasis. In Parkinson's disease (PD), Hsp90 paradoxically contributes to pathology by stabilizing toxic client proteins, particularly misfolded [alpha-synuclein](/proteins/alpha-synuclein), which drives the formation of Lewy bodies and dopaminergic neuron death. Hsp90 inhibitors represent a promising therapeutic strategy that promotes the degradation of these toxic client proteins through the proteasome and autophagy pathways, offering potential disease-modifying benefits for PD patients.
Hsp90 Biology and Structure
Molecular Architecture Hsp90 is a 90 kDa homodimeric chaperone present at 1-2% of total cellular protein, making it one of the most abundant cytosolic proteins. Its structure consists of three functional domains:
N-terminal domain (NTD) : The ATP-binding pocket (residues 1-220) is the primary target for Hsp90 inhibitors. This domain undergoes dramatic conformational changes during the chaperone cycle, transitioning between open and closed states.Middle domain (MD) : Positioned at residues 221-290, this domain serves as the primary client protein binding site.C-terminal domain (CTD) : The dimerization domain (residues 291-605) mediates Hsp90 homodimer formation.The Chaperone Cycle Under normal cellular conditions, Hsp90 operates through an ATP-dependent cycle:
Open conformation : Hsp90 adopts an open V-shaped conformationATP binding : Triggers N-terminal dimerization and closed conformationClient protein folding : Facilitates client protein folding with co-chaperonesATP hydrolysis : Drives conformational changes and client releaseReset : The cycle repeats with new client protein loading
Hsp90 in Parkinson's Disease Pathogenesis
Alpha-Synuclein Stabilization In PD pathogenesis, Hsp90 plays a detrimental role by stabilizing toxic forms of alpha-synuclein:
Oligomer stabilization : Hsp90 binding promotes toxic oligomer formationAggregation protection : Extends half-life of misfolded alpha-synucleinSeeding activity : Hsp90-alpha-synuclein complexes may have enhanced seeding capacityCell-to-cell transmission : Facilitates pathology spread between neuronsClient Protein Dysregulation
Mechanistic Link to Neurodegeneration The Hsp90-alpha-synuclein interaction creates a vicious cycle:
Mermaid diagram (expand to render)
Therapeutic Rationale for Hsp90 Inhibition Hsp90 inhibitors offer multiple therapeutic benefits:
Proteasomal degradation : Promotes ubiquitin-dependent degradationAutophagy induction : Targets released clients to autophagyReduced aggregation : Lowers steady-state alpha-synuclein levelsNeuroprotection : Combined effects on multiple toxic proteins
Molecular Mechanism of Action When Hsp90 is inhibited:
Client protein release : Misfolded proteins are released from Hsp90Ubiquitination : Released proteins are targeted for degradationProteasome recruitment : Ubiquitinated proteins are degradedAutophagy activation : Larger aggregates are cleared via autophagy
Hsp90 Inhibitor Classes
First-Generation: Geldanamycin Derivatives
Geldanamycin : Prototypical Hsp90 inhibitor from Streptomyces hygroscopicus First discovered as anticancer agent
Significant hepatotoxicity limits clinical use
17-AAG (Tanespimycin) : Improved solubility, reduced hepatotoxicitySuccessfully completed Phase I trials
Neuroprotective in PD models
17-DMAG (Alvespimycin) : Water-soluble, demonstrated neuroprotective effects in PD modelsBetter tissue distribution
Currently in preclinical development for PD
Second-Generation: Synthetic Small Molecules
PU-H71 : Purine-scaffold with brain penetration, in clinical trialsShows affinity for tumor Hsp90
Blood-brain barrier penetration demonstrated
AUY922 (Luminespimycin) : Isoflavone-derived with potent inhibitionStrong anti-tumor activity
Limited CNS penetration
NVP-HSP990 : Excellent oral bioavailabilityNovartis compound
Phase 1 completed
AT13387 (Onalespib) : Long-acting with sustained target engagementDemonstrated safety in Phase 1
Third-Generation: CNS-Optimized
PU-DZ8 : Designed for CNS applications with optimized brain penetrationKW-2478 : Synthetic with favorable pharmacokineticsEXEL-0466 : Recently developed with enhanced CNS penetrationPreclinical Evidence in PD Models
In Vitro Studies
Primary neuronal cultures : 17-DMAG reduces alpha-synuclein toxicityDose-dependent neuroprotection
Reduces oligomer formation
LUHMES cells : Reduced aggregation and increased survivalDopaminergic neuronal cell line
Validates translational potential
Patient-derived iPSCs : Dopaminergic neurons respond to treatmentDirect relevance to human disease
In Vivo Models
AAV-alpha-synuclein models : Protect dopaminergic neuronsReduced neuron loss in substantia nigra
Improved motor performance
Transgenic mice : Improved motor performanceReduced alpha-synuclein aggregation
Improved survival
MPTP/6-OHDA models : Neuroprotection against toxin-induced degenerationPreserved dopaminergic terminals
Maintained striatal dopamine levels
Key Findings Summary
Clinical Development Status
Clinical Challenges
Brain penetration : Remains suboptimal for many compoundsPeripheral toxicity : Limits maximum tolerated dosesMultiple client protein effects : May cause unintended consequencesPatient selection : Biomarkers for target engagement neededCombination Therapies
With Autophagy Enhancers Combining Hsp90 inhibitors with autophagy inducers may provide synergistic benefits:
Rapamycin/mTOR inhibitors : Enhanced autophagyTrehalose : Autophagy inducer with neuroprotective propertiesCarbamazepine : TFEB activationWith Chaperones
Hsp70 inducers : Complementary protein clearanceHsp40 co-chaperones : Client protein targetingBiomarkers and Patient Selection
Target Engagement Biomarkers
Hsp90 client proteins : LRRK2, PINK1 levels in PBMCsAlpha-synuclein aggregates : CSF RT-QuICHeat shock factor 1 (HSF1) activation : Upstream biomarkerPatient Selection Criteria
Genetically defined : LRRK2, GBA mutation carriers may benefit mostDisease stage : Early intervention may be most effectiveBiomarker positive : Evidence of abnormal protein aggregationSafety Considerations
Adverse Effects
Hepatotoxicity : Liver function monitoring requiredFatigue : Common with systemic Hsp90 inhibitionGastrointestinal : Nausea, diarrheaVisual disturbances : With some compoundsContraindications
Severe hepatic impairment
Pregnancy/breastfeeding
Concurrent hepatotoxic medications
Future Directions
Brain-penetrant compounds : Continued optimization of CNS penetrationCombination approaches : Synergistic strategies with autophagy enhancersSelective client targeting : Developing compounds that preferentially release specific clientsBiomarker development : Patient selection and target engagementGene-specific approaches : Tailored for LRRK2, GBA carriersSee Also
[Alpha-Synuclein](/proteins/alpha-synuclein)
[LRRK2](/genes/lrrk2)
[GBA](/genes/gba)
[Protein Homeostasis in PD](/mechanisms/protein-homeostasis-parkinsons)
[Molecular Chaperones](/mechanisms/molecular-chaperones-neurodegeneration)
References
[Kirkpatrick et al., Hsp90 and alpha-synuclein aggregation (2005)](https://doi.org/10.1073/pnas.0505307102)
[Wang et al., Hsp90 inhibition in PD models (2008)](https://doi.org/10.1093/brain/awn134)
[Chu et al., Hsp90 as therapeutic target in PD (2019)](https://doi.org/10.1002/mds.27769)
[Makarava et al., Chaperone-based therapy for synucleinopathies (2022)](https://doi.org/10.1002/mds.29103)
[Chen et al., Hsp90 in synucleinopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38040085)
[Niedzielska et al., Hsp90 and LRRK2 in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/39551273)
[Shen et al., HDAC6-Hsp90 crosstalk in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34298079)
[Cuervo et al., Autophagy and chaperones in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32058412)
[Luthra et al., PU-H71 in neurodegenerative models (2023)](https://pubmed.ncbi.nlm.nih.gov/41767843)
[Auluck et al., Hsp70 and alpha-synuclein aggregation (2002)](https://pubmed.ncbi.nlm.nih.gov/11850676)
[Fujita et al., Geldanamycin derivatives in Parkinson's disease models (2007)](https://pubmed.ncbi.nlm.nih.gov/17693408/)
[Tatro et al., Hsp90 client protein profiling in PD (2009)](https://pubmed.ncbi.nlm.nih.gov/19342225/)
[McCormack et al., Hsp90 inhibitors and autophagy (2010)](https://pubmed.ncbi.nlm.nih.gov/20851858/)
[Daturpalli et al., Hsp90-α-synuclein interaction (2018)](https://pubmed.ncbi.nlm.nih.gov/29526653/)
[Sanchez-Valle et al., Hsp90 inhibition reduces Lewy body pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35653788/)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[HSP90-Tau Disaggregation Complex Enhancement](/hypothesis/h-0f00fd75) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: HSP90AA1
[TFEB-PGC1α Mitochondrial-Lysosomal Decoupling](/hypothesis/h-e5a1c16b) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
[The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction](/hypothesis/h-e3e8407c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
Related Analyses:
[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
[Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v5-20260402) 🔄
Show full description